Skip to main content
. 2019 Sep 4;14(9):e0222002. doi: 10.1371/journal.pone.0222002

Table 1. Demographic and clinical characteristics of participants.

Item Controls PD p-value
Number of participants 20 32 -
Female/Male 10/10 18/14 0.878
Age 69.06 ± 6.86 69.36 ± 5.82 0.868
LED - 523.36 ± 295.31 -
Disease duration - 5.16 ± 3.62 -
eTIV (cm3) 156.81 ± 15.84 152.06 ± 17.71 0.333
Years of education 13.14 ± 3.68 9.78 ± 6.05 0.042
Relative displacement 0.13 ± 0.06 0.16 ± 0.06 0.066
H&Y - 1.75 ± 0.55 -
UPDRS-III 2.40 ± 3.02 10.69 ± 7.06 <0.001
TUG 8.60 ± 1.54 9.68 ± 2.39 0.079
MMSE 28.8 ± 1.2 28.28 ± 1.42 0.18
AQT 57.25 ± 15.09 66.47 ±14.78 0.035
AF 24.80 ± 6.59 23.03 ± 5.67 0.309

Data presented as mean ± standard deviation; p-values, one-way independent samples t-test, excluding male/female numbers which was analyzed via a chi-square test for independence; LED, levodopa equivalent dosage (mg); eTIV, estimated total intracranial volume; Relative displacement, mean value derived from MCFLIRT FSL motion correction; H&Y, Hoehn and Yahr Scale; UPDRS-III, Unified Parkinson’s Disease Rating Scale part III; TUG, Timed Up and Go test; MMSE, Mini Mental-state Examination; AQT, A quick test of cognitive speed; AF, Animal fluency test